Companies › Shenzhen TargetRx
4 active drug programs in 8 registered trials: 5 Phase 1, 2 Phase 2, 1 Phase 3; Oncology; next expected readout Feb 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| TGRX-326 ALK inhibitor | ALK | Phase 3 | Non Small Cell Lung Cancer; Non-small Cell Lung Cancer | Nov 2028 |
| TGRX-678 BCR-ABL1 tyrosine kinase inhibitor | – | Phase 2 | Chronic Myeloid Leukemia; Chronic Myelogenous Leukemia | Dec 2027 |
| TGRX-1942 | – | Phase 1 | Non Small Cell Lung Cancer | Feb 2027 |
| TGRX-814 | – | Phase 1 | Hematologic Malignancy | Feb 2029 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT05955391 | TGRX-326 | Phase 2 | Non-small Cell Lung Cancer | Oncology | Dec 2024 |
| NCT05441956 | TGRX-326 | Phase 1 | Non-small Cell Lung Cancer | Oncology | Aug 2025 |
| NCT05434312 | TGRX-678 | Phase 1 | Chronic Myelogenous Leukemia | Oncology | Mar 2026 |
| NCT06484816 | TGRX-1942 | Phase 1 | Non Small Cell Lung Cancer | Oncology | Feb 2027 |
| NCT06088888 | TGRX-678 | Phase 1 | Chronic Myelogenous Leukemia | Oncology | Dec 2027 |
| NCT06453902 | TGRX-678 | Phase 2 | Chronic Myeloid Leukemia | Oncology | Apr 2028 |
| NCT06082635 | TGRX-326 | Phase 3 | Non Small Cell Lung Cancer | Oncology | Nov 2028 |
| NCT06206174 | TGRX-814 | Phase 1 | Hematologic Malignancy | Oncology | Feb 2029 |
Xcovery Holdings CStone Pharmaceuticals Nuvalent Shanghai Fosun Pharmaceutical Industrial Development Lantheus Medical Imaging
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.